Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06654089 · ClinicalTrials.gov registry record · Phase 4

A Study Evaluating Quality of Life Parameters Following Use of Emergen-C

A Phase 4 study, sponsored by HALEON.

Completed
Registry status
Phase 4
Development phase
299
Enrollment target

NCT06654089 is a Phase 4 study that has completed, run by HALEON. The registered enrollment target is 299 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06654089, a Phase 4 study, has completed, sponsored by HALEON.

COMPLETED
Registry status
Phase 4
Development phase
299 participants
Enrollment target

Study Summary

The purpose of this study is to determine how Emergen-C use can improve quality of life (QoL) in a real-world setting to help consumers and healthcare professionals understand the benefits of taking Emergen-C on a routine or daily basis.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Emergen-C Core Super Orange Powder

Trial Details

FieldValue
Enrollment Target 299 participants
Start Date 2024-10-30
Est. Completion 2025-02-24
Phase Phase 4

Sponsor

HALEON

34 total trials

What the Registry Record Tells You About NCT06654089

The ClinicalTrials.gov registry entry for NCT06654089 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HALEON, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06654089 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06654089 about?

NCT06654089 is a clinical study titled "A Study Evaluating Quality of Life Parameters Following Use of Emergen-C". The purpose of this study is to determine how Emergen-C use can improve quality of life (QoL) in a real-world setting to help consumers and healthcare professionals understand the benefits of taking Emergen-C on a routine or daily basis.

What is the current status of trial NCT06654089?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 299 participants. The study started on 2024-10-30. Estimated completion is 2025-02-24.

What interventions are being tested in trial NCT06654089?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Emergen-C Core Super Orange Powder (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06654089?

This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.